Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes. Its flagship products include the t:slim X2 insulin delivery system and the Tandem Mobi insulin pump, which is an automated insulin delivery system. The company also sells single-use products such as cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. Additionally, Tandem offers the Tandem Device Updater for updating pump software from a personal computer, and the Tandem Source web-based data management platform that visually displays diabetes therapy management data from pumps and integrated CGMs. The portfolio also includes Sugarmate, a mobile app that helps users visualize diabetes therapy data.

Tandem Diabetes Care is listed on the NasdaqGM exchange under the ticker symbol TNDM. Its stock trades in United States Dollars (USD). The company is headquartered in San Diego, California, and operates primarily in the United States, though it also serves global markets.

Tandem Diabetes Care operates in the Healthcare sector and is classified under the Medical Devices industry. The company focuses on developing technology solutions for diabetes management, including insulin delivery systems and data management platforms. As a medical device company, its products are designed to improve the quality of life for people living with diabetes by offering advanced, user-friendly insulin pump systems and related accessories.

Tandem Diabetes Care is headquartered in San Diego, California, United States. The company was originally incorporated in 2006 as Phluid Inc. and rebranded to Tandem Diabetes Care in January 2008. It serves customers in the United States and globally, with a focus on providing insulin delivery systems and diabetes management solutions. The company's products, such as the t:slim X2 and Tandem Mobi pumps, are used by people with diabetes worldwide.

Tandem Diabetes Care generates revenue primarily through the sale of its insulin delivery systems and related consumables. The company's flagship products include the t:slim X2 insulin delivery system and the Tandem Mobi automated insulin delivery pump. Recurring revenue comes from single-use products such as insulin cartridges and infusion sets, which are regularly replaced by users. Additionally, Tandem offers software solutions like the Tandem Device Updater and Tandem Source data management platform, which may be bundled with hardware or sold separately. The company also has a collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems, which could lead to future product innovations.